Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EACR 2016 /
ERß expression predicts breast cancer risk in hyperplasia

9th - 12th Jul 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.07.16
Views: 2301

Dr Tina Hieken - Mayo Clinic, Rochester, USA

Dr Hieken speaks with ecancertv at EACR 2016 about the significance of a potential biomarker for breast cancer in hyperplasia patients.

She describes how the subpopulation of patients, those with atypical hyperplasia of the breast and high levels of ERß, can act on this information with further breast cancer treatment, and the choice faced in risk reduction.

Dr Hieken also summarises the interests and technologies being investigated in her lab, and the future of breast cancer prevention.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation